gantenerumab (RG1450) / MorphoSys, Novartis, Roche 
Welcome,         Profile    Billing    Logout  

6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
gantenerumab (RG1450) / Roche, Novartis
NCT03444870 / 2017-001364-38: Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

Checkmark GRADUATE-1 and GRADUATE-2 studies
Jun 2018 - Jun 2018: GRADUATE-1 and GRADUATE-2 studies
Terminated
3
1053
Europe, Canada, Japan, US, RoW
Gantenerumab, RO4909832, Placebo
Hoffmann-La Roche
Alzheimer Disease
12/22
02/23
NCT04374253 / 2020-000766-42: A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)

Terminated
3
1382
Europe, Canada, Japan, US, RoW
Gantenerumab
Hoffmann-La Roche
Alzheimer Disease
03/23
03/23
SKYLINE, NCT05256134 / 2021-001184-25: A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)

Terminated
3
24
Europe, Canada, US, RoW
Gantenerumab, Placebo
Hoffmann-La Roche
Alzheimers Disease
03/23
03/23
DIAN-TU, NCT06424236: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation

Terminated
2/3
73
Europe, Canada, US, RoW
Gantenerumab, RO4909832
Washington University School of Medicine, Hoffmann-La Roche, Alzheimer's Association, National Institute on Aging (NIA)
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
08/23
11/23
DIAN-TU, NCT01760005 / 2013-000307-17: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol -001

Checkmark From DIAN-TU trial
Feb 2020 - Feb 2020: From DIAN-TU trial
Checkmark Top-line data from DIAN-TU trial in rare inherited form of Alzheimer's disease
Feb 2020 - Feb 2020: Top-line data from DIAN-TU trial in rare inherited form of Alzheimer's disease
Checkmark DIAN TU: N=210
More
Recruiting
2/3
490
Europe, Canada, Japan, US, RoW
Gantenerumab, RO4909832, Solanezumab, LY2062430, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab), E2814, Lecanemab, BAN2401, Matching Placebo (E2814)
Washington University School of Medicine, Eli Lilly and Company, Hoffmann-La Roche, Alzheimer's Association, National Institute on Aging (NIA), Avid Radiopharmaceuticals, Accelerating Medicines Partnership (AMP), Eisai Inc., Janssen, LP
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
10/27
10/27
NCT04592341 / 2020-001384-87: A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

Terminated
2
192
Europe, US
Gantenerumab
Hoffmann-La Roche
Alzheimer Disease
01/23
03/23

Download Options